Diagnostic assay for cancer

• US 6,440,676 B1
• Filed: 09/25/2000
• Issued: 08/27/2002
• Est. Priority Date: 11/12/1998
• Status: Expired due to Fees

• Current Assignee: Nyxis Neurotherapies, Inc. (Abbvie Incorporated)
• Original Assignee: Nyxis Neurotherapies, Inc. (Abbvie Incorporated)
• Inventors: Kroes, Roger A., Yamamoto, Hirotaka, Moskal, Joseph R.
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): Chakrabarti, Arun K.
• Application Number:
  US09/668,885
• Time in Patent Office: 701 Days
• Field of Search: 435/6, 435/91.2, 536/22.1, 536/24.3
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The invention is directed towards gene expression characteristic for cancer, in particular brain cancers such as glioblastoma. Compositions, methods and kits encompassing such therein.

Claims

1. A method for determining the effectiveness of a treatment regimen for brain cancer, the method comprising:

(a) removing a control biological sample from a patient prior to treatment;

(b) determining the amount of transcription in the control biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;

(c) removing a test biological sample from a patient following treatment; and

(d) determining the amount of transcription in the test biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;

wherein a decreased amount of transcription in the test sample relative to the control sample indicates that the treatment regimen for brain cancer is effective.

2. The method of claim 1, wherein the nucleic acid transcript is detected by RT-PCR using at least one gene specific amplification primer.

3. The method of claim 1, wherein the nucleic acid transcript is detected by nucleic acid hybridization using at least one gene specific probe.

4. The method of claim 1, wherein the nucleic acid transcript is detected by in situ hybridization.

5. The method of claim 1, wherein the nucleic acid transcript is detected by RNase protection assay.

6. A method for determining the effectiveness of a treatment regimen for breast cancer, the method comprising:

(a) removing a control biological sample from a patient prior to treatment;

(b) determining the amount of transcription in the control biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;

(c) removing a test biological sample from a patient following treatment; and

,

(d) determining the amount of transcription in the test biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;

wherein a decreased amount of transcription in the test sample relative to the control sample indicates that the treatment regimen for breast cancer is effective.

7. The method of claim 6, wherein the nucleic acid transcript is detected by RT-PCR using at least one gene specific amplification primer.

8. The method of claim 6, wherein the nucleic acid transcript is detected by nucleic acid hybridization using at least one gene specific probe.

9. The method of claim 6, wherein the nucleic acid transcript is detected by in situ hybridization.

10. The method of claim 6, wherein the nucleic acid transcript is detected by RNase protection assay.